Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antihistamine Forced Switch Proposal Returns In Citizen Petition

This article was originally published in The Tan Sheet

Executive Summary

A law firm seeks to cut its own health care costs as well as direct FDA's attention to previous citizen petitions to switch Rx antihistamines to OTC with a petition asking FDA to switch Sanofi-Aventis's Allegra and Pfizer's Zyrtec
Advertisement

Related Content

Despite EC Switch Denial, Attorneys See Value In Non-Sponsor Petitions
Despite EC Switch Denial, Attorneys See Value In Non-Sponsor Petitions
Zyrtec-D Switch Approved – J&J Will Launch Behind The Counter This Year
Antihistamine switch petition gains support
FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
Schering OTC Claritin Coupons Appearing In Newspapers Dec. 15
Clarinex Clinical, Safety Characteristics Support OTC Use – WellPoint
Clarinex Clinical, Safety Characteristics Support OTC Use – WellPoint
FDA Forced OTC Switch Process Ambiguities Revealed At Subcmte. Hearing
FDA, Rx Antihistamine Makers' Next Move: Compromise?

Topics

Advertisement
UsernamePublicRestriction

Register

PS100326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel